Search Results
Your search for ,HIS matches 4456 pages
Showing 4051 - 4100Eduardo M. Sotomayor, MD, Named Director of GW Cancer Center
The George Washington University (GW) School of Medicine and Health Sciences (SMHS), the GW University Hospital, and the GW Medical Faculty Associates announced the appointment of Eduardo M. Sotomayor, MD, as the inaugural Director of the GW Cancer Center (GWCC). He will also serve as a Professor...
Long-Term Survival Advantage Seen With Intraperitoneal vs Intravenous Chemotherapy in Advanced Ovarian Cancer
In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Devansu Tewari, MD, of Kaiser Permanente Irvine Medical Center, and colleagues found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous...
Expert Point of View: Andrew B. Lassman, MD
Formal discussant, Andrew B. Lassman, MD, of the Department of Neurology at Herbert Irving Comprehensive Cancer Center and Columbia University Medical Center in New York, congratulated Dr. Brown and his coauthors for undertaking and completing a “herculean task” that took 10 years. To illustrate...
Clinically Meaningful Preliminary Results With Pembrolizumab in Recurrent Head and Neck Cancer
Pembrolizumab (Keytruda) is making inroads into head and neck cancer, with encouraging results in heavily pre-treated patients with recurrent or metastatic squamous cell carcinoma of the head and neck, according to a report on the expansion-cohort KEYNOTE-012 study presented at the 2015 ASCO...
Clinical Trials, Drug Costs, and Restoring the Primacy of the Patient Volunteer
“What’s past is prologue.” —William Shakespeare Today, a cancer drug under study in a clinical trial is commonly provided for a finite period of time after the study closes to accrual. If that drug were not yet U.S. Food and Drug Administration (FDA)-approved when the study began, the complimentary ...
Sexual Dysfunction After Gynecologic Cancer Treatment
A study presented at the ASCO Annual Meeting showed decreased sexual activity in women following treatment for gynecologic cancers, down from 6 to 7 times per month before treatment to 3 to 5 times per month after treatment (abstract 9592). “[Sexual dysfunction] is a topic that not many people want ...
Response to May 10 Cartoon
As a medical writer specializing in oncology, an ASCO member, and someone who tries to build sensitivity to patients into all my work, I was concerned about the cartoon I saw in the May 10, 2015, issue of The ASCO Post. On page 46, there is a cartoon of someone being thrown off a cliff because he...
Carpe Diem
My life as a cancer survivor and an oncologist has taught me the importance of living every day to the fullest. Sometimes we all need a little reminding to appreciate life to the fullest. When I think of my former patient, Marc, that is what comes to mind. When I was a senior in high school, I was...
Redefining Cancer
The ability to interrogate cancer cells at the genomic, proteomic, immunologic, and metabolomic levels will transform oncology care from one that relies mainly on trial-and-error treatment strategies based on the anatomy of the tumor to one that is more precisely based on the tumor’s molecular...
Elective Neck Dissection Beats Watch and Wait Approach in Early Oral Cancer
Elective neck dissection of node-negative early-stage oral cancer at the time of primary surgery improves overall survival and disease-free survival compared with therapeutic neck dissection (ie, therapeutic neck dissection at the time of nodal relapse, or “watch and wait” approach), according to a ...
Frederick Pei Li, MD, Pioneer of Cancer Genetics, Dies at 75
Frederick Pei Li, MD, who helped inaugurate the era of cancer genetics by demonstrating that people can inherit a genetic susceptibility to develop certain malignancies, died on June 12 at the age of 75. A Professor at Dana-Farber Cancer Institute, Harvard Medical School, and Harvard T.H. Chan...
Date of Last Chemotherapy Is Not a Proxy for Deciding When to Stop Treating Metastatic NSCLC
“Patients, their families, and oncologists recognize the administration of chemotherapy near death as aggressive and poor-quality care,” William F. Pirl, MD, MPH, and colleagues from Massachusetts General Hospital, Boston, wrote in the Journal of Oncology Practice. “However, rates have been slowly...
Building and Adjusting to My Life After Cancer
I had been watching a lump in my left breast for signs of cancer for 10 years, from around the time I was 21. Screening tests had failed to find any tissue abnormality, and my doctor said I was too young to have cancer, so I wasn’t overly concerned. But when I noticed the lump getting bigger in...
Noted Pediatric Oncologist, Robert J. Arceci, MD, PhD, Dies
Over the past 50 years, great strides have been made in diagnosis, treatment, and survival of childhood cancer. In the 1960s, the probability of survival for a child with cancer was less than 25%, whereas today it may exceed 80%. This incredible cancer success story has been made possible by the...
Clara D. Bloomfield, MD, FASCO: Never One to Back Down From a Challenge
Clara D. Bloomfield, MD, FASCO, always sat in the front row at school. She grew up during a rigidly paternalist period in American society, and her early feminist leanings were brushed aside as grade-school adventures. The medical school lecture room of the 1960s was a male-dominated culture, and...
First Winners of Tri-Institutional Breakout Awards Announced
Six young scientists at Memorial Sloan Kettering Cancer Center, Rockefeller University, and Weill Cornell Medical College have been named the inaugural winners of a new prize established to recognize postdoctoral investigators in the life sciences. The Tri-Institutional Breakout Awards for Junior...
The Mind-Body Program in Action
Here are several real-life examples of the positive effects of the mind-body program, shared by Robin Hardbattle, MS, LAc, and the parents of children who benefited from it. Breathing Practices and Guided Imagery: Prior to learning breathing practices and guided meditation, Matt, a 12-year-old...
Roberto Pili, MD, Expert in Prostate, Renal, and Bladder Cancers, Joins Indiana University Simon Cancer Center
Roberto Pili, MD, a nationally recognized expert in prostate, renal, and bladder cancers, has joined the Indiana University (IU) Melvin and Bren Simon Cancer Center. Dr. Pili is the Robert Wallace Miller Professor of Oncology at the Indiana University School of Medicine and Researcher at the IU...
ASCO QOPI® Certification Program Benefits Oncology Practices and Patients
Christa Braun-Inglis, MS, NP, has seen her last three practices certified through ASCO’s Quality Oncology Practice Initiative (QOPI®). Ms. Braun-Inglis, a nurse practitioner with Kaiser Hawaii Region, was not solely responsible for the designations, although she helped some of the practices become...
Bert Vogelstein, MD, Receives 2015 Dr. Paul Janssen Award for Biomedical Research
Johnson & Johnson named Bert Vogelstein, MD, of Johns Hopkins University, Johns Hopkins Kimmel Cancer Center, and the Howard Hughes Medical Institute, the winner of the 2015 Dr. Paul Janssen Award for Biomedical Research for his breakthroughs in oncology research, which have spanned more than 2 ...
Predicting Recurrence After Surgery in Renal Cell Carcinoma: 16-Gene Assay Recurrence Score Ushers in New Era
In a study reported in The Lancet Oncology and reviewed in this issue of The ASCO Post, Brian Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues showed that a 16-gene assay recurrence score could predict postoperative outcome in patients with stage I to III clear cell renal...
Five Presidential Appointees Named to National Cancer Advisory Board
President Barack Obama recently announced his intent to nominate the following individuals to the National Cancer Advisory Board: Peter C. Adamson, MD; Yuan Chang, MD; Timothy J. Ley, MD; Deborah Watkins Bruner, RN, PhD, FAAN; and Max S. Wicha, MD. Peter C. Adamson, MD Dr. Adamson is Attending...
Oncolytic Immunotherapy in Melanoma: It’s Not All About PD-1
The benefit from immune-directed therapies in patients with advanced melanoma is not limited to the exploding field of checkpoint inhibitors. According to Robert Andtbacka, MD, Associate Professor of Surgical Oncology, at the Huntsman Cancer Institute at the University of Utah, Salt Lake City,...
Poliovirus for Glioblastoma Grabs National Attention
Researchers at The Preston Robert Tisch Brain Tumor Center at Duke University are being barraged by patients wishing to enroll in their clinical trial of an engineered poliovirus for recurrent glioblastoma. This comes as a result of a CBS 60 Minutes interview with lead researcher Matthias...
Cost of Immunotherapy Projected to Top $1 Million per Patient per Year
If new immunotherapy combinations were administered to the half a million Americans dying of cancer each year, the nation’s price tag for treating them—for just 1 year—could top $174 billion, according to projections by Leonard Saltz, MD, Chief of Gastrointestinal Oncology and Chair of the Pharmacy ...
UAB Study on Lay Navigation Program Shows Trend Toward Cost Savings
Researchers from the University of Alabama at Birmingham (UAB) presented preliminary findings of an observational study indicating a rapid decline in Medicare costs and patient resource utilization during implementation of a lay navigation program. The study was presented at this year’s ASCO Annual ...
How CancerLinQ™ Can Benefit People Living With Cancer
As a regular readers of The ASCO Post know, ASCO is developing an exciting new health information learning system called CancerLinQ™, which will exponentially enlarge our understanding of cancer therapy far beyond what we’ve achieved with our system of clinical trials. Cancer clinical trials have...
Irwin Rose, PhD, Nobel Laureate and Biochemist, Dies at 88
Scientist and Nobel Laureate Irwin “Ernie” Rose, PhD, passed away June 2, 2015, after a long illness. He was 88. Dr. Rose shared the 2004 Nobel Prize for chemistry with Aaron Ciechanover, MD, DSc, and Avram Hershko, MD, PhD, of the Israel Institute of Technology for their pioneering work in...
Michael O'Malley, PhD, MPH, Former UNC Lineberger Associate Director, Dies at 64
Michael O’Malley, PhD, MPH, former Associate Director of the University of North Carolina (UNC) at Chapel Hill’s Lineberger Comprehensive Cancer Center and former Adjunct Associate Professor of Health Policy and Management at UNC’s Gillings School of Global Public Health, has passed away...
Preeminent Cancer Researcher Brian E. Henderson, MD, Dies
Brian E. Henderson, MD, began his medical path as a researcher in virology, and as a young scientist, he ventured to Africa as part of a Centers for Disease Control team to study yellow fever. The better part of his esteemed medical career, however, was as one of the world’s most respected...
My Faith Helped Me Choose a Way Forward With Cancer
I've been fortunate to be strong and healthy for most of my life. In fact, there is no history of any serious illness in my family, which is why I was so unprepared to hear the words “You have breast cancer” 5 years ago. Not only was the diagnosis foreign to me, I had no idea what chemotherapy and...
Memorial Sloan Kettering Cancer Center Receives Gift of $150 Million From David H. Koch
Memorial Sloan Kettering Cancer Center (MSK) announced that it has received the largest gift in its history, a commitment of $150 million, from long-time MSK board member David H. Koch. This unprecedented contribution will fund a state-of-the-art outpatient medical facility to be known as The David ...
John A. Zaia, MD, Named Director of Center for Gene Therapy at City of Hope
Gene therapy pioneer John A. Zaia, MD, has been named Director of the Center for Gene Therapy within City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute. Internationally known and respected for his groundbreaking research into potential gene therapy treatments for HIV,...
Matthew Trunnell Named Vice President and Chief Information Officer at Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center announced the appointment of Matthew Trunnell as its Vice President and Chief Information Officer (CIO). Mr. Trunnell has worked at the intersection of information technology and life sciences research in both academic and commercial environments in support of ...
ASCO, Conquer Cancer Foundation Congratulate 2015 Grant and Award Recipients
The Conquer Cancer Foundation of ASCO presented more than $6.7 million in grants and awards to more than 200 promising oncology researchers at the 2015 ASCO Annual Meeting. The Conquer Cancer Foundation and ASCO congratulate the recipients on their contributions to the field of oncology and offer...
Cyrus Ghajar, PhD, Receives $4.1 Million From Department of Defense
Cyrus Ghajar, PhD, a metastatic breast cancer researcher at Fred Hutchinson Cancer Research Center, has received a $4.1 million Department of Defense Breast Cancer Research Program (BCRP) “Era of Hope” Scholar Award. The Department of Defense’s BCRP is the second biggest funder of breast cancer...
Expert Point of View: Keith T. Flaherty, MD
Keith T. Flaherty, MD, Associate Professor of Medicine, Harvard Medical School, and Director of the Termeer Center for Targeted Therapy, Boston, was interviewed by The ASCO Post for his thoughts on the findings from Atreya and colleagues. He believes the study’s outcomes are sufficient for...
Kevin Fitzpatrick Named CEO of CancerLinQ LLC
Kevin Fitzpatrick has been named CEO of CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO. Mr. Fitzpatrick, who is currently the Executive Vice President and Chief Innovation Officer of the American College of Cardiology (ACC), will begin his new role on August 3. CancerLinQ LLC was...
Jonathan D. Licht, MD, Appointed Director of the University of Florida Health Cancer Center, Gainesville
Jonathan D. Licht, MD, has been appointed Director of the University of Florida (UF) Health Cancer Center, Gainesville. His appointment will go into effect on October 1. Dr. Licht comes to UF Health from Northwestern University. He is currently Associate Director for Clinical Sciences at the...
George Wilding, MD, Named Vice Provost for Clinical and Interdisciplinary Research at MD Anderson
The University of Texas MD Anderson Cancer Center is pleased to announce the appointment of George Wilding, MD, as Vice Provost for Clinical and Interdisciplinary Research, effective September 1. Prior to joining MD Anderson, Dr. Wilding served on the institution’s external advisory board. He also...
ASTRO Guidelines on Radiotherapy in Locally Advanced NSCLC: A Good Place to Start
ASCO’s endorsement of the American Society for Radiation Oncology (ASTRO) guidelines on the role of radiotherapy in locally advanced non–small cell lung cancer (NSCLC) is an important summary of the best evidence on the appropriate role and techniques for radiotherapy in this disease.1 These...
Medicare to Reimburse Doctors for End-of-Life Counseling
In a breakthrough proposal announced on July 8, the Centers for Medicare & Medicaid Services (CMS) plans to reimburse physicians for end-of-life counseling, a move that the oncology community has long been lobbying for. Arriving just as the presidential election cycle begins to heat up, the CMS ...
Charles Roberts, MD, PhD, Named Director of St. Jude Comprehensive Cancer Center
St. Jude Children’s Research Hospital has named Charles W.M. Roberts, MD, PhD, Executive Vice President and Director of the St. Jude Comprehensive Cancer Center in Memphis, the first and only National Cancer Institute (NCI)-designated Comprehensive Cancer Center devoted solely to children. Dr....
Mount Sinai Honors James F. Holland, MD, FASCO, on the Occasion of His 90th Birthday
On May 14, 2015, over 160 colleagues, family members, friends, and patients of James F. Holland, MD, FASCO, gathered in the Goldwurm Auditorium in the Icahn School of Medicine at Mount Sinai Hospital in New York to honor Dr. Holland for the contributions he has made during his remarkable career in ...
Cost vs Our Values in Cancer Care
An 80-year-old patient with metastatic prostate cancer asked me to discontinue his treatments, which were costing him more than $1,000 every 3 months. Although he had Medicare, he did not have secondary insurance. I told him that I would seek compassionate-care payment from the pharmaceutical...
Charles Rubin, MD, Pediatric Cancer Specialist, Dies at 62
Charles M. Rubin, MD, Associate Professor of Pediatrics at the University of Chicago Medicine, a highly respected specialist in the care of children with cancer, died on July 17. He was 62. An authority on all aspects of pediatric cancers, Dr. Rubin had a particular interest in brain tumors and...
A Lasting Legacy
When Emil J Freireich, MD, retires from the University of Texas MD Anderson Cancer Center on September 1, he will have spent 50 years at the institution and a total of 60 years in the pursuit of curing childhood leukemia as well as other cancers and in the educational development of young...
Timothy L. Lash, DSc, MPH, Named Head of Winship’s Cancer Prevention and Control Program
Winship Cancer Institute of Emory University has named Timothy L. Lash, DSc, MPH, Professor of Epidemiology in the Rollins School of Public Health and Winship member, as the new Leader for the Winship Cancer Prevention and Control (CPC) Research Program. His position takes effect immediately....
Translational Research: Dogs and Humans Nearly Interchangeable in the Laboratory
“Between animal and human medicine there is no dividing line—nor should there be. The object is different but the experience obtained constitutes the basis of all medicine.” — Rudolf Virchow (1821–1902) Everyone has seen photographs of people who look like their dogs: the young woman with long...
Michael Allen Pulsipher, MD, Joins Children’s Hospital Los Angeles
Michael Allen Pulsipher, MD, joined the Children’s Center for Cancer and Blood Diseases and the Division of Hematology, Oncology, and Blood and Marrow Transplantation at Children’s Hospital Los Angeles (CHLA) as Head of the Section of Blood and Marrow Transplantation (BMT) and as BMT Clinical...
